Aude Charbonnier

Laboratoire de Biologie et Modélisation de la Cellule — France

Medicine · Health Sciences

32h-index6.9kcitations156works6.12yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Myeloid Leukemia Treatments(75), Acute Myeloid Leukemia Research(62), Chronic Lymphocytic Leukemia Research(56), Eosinophilic Disorders and Syndromes(34), Acute Lymphoblastic Leukemia research(27)

Publications155 total

Additional genetic abnormalities (AGA) and microhomology end-joining DNA repair (MMEJ) signatures influence the outcome of newly diagnosed chronic phase (CP) CML: Ancillary study of the Trial of imatinib after ponatinib induction (TIPI)
Blood·2025Open Access
CML-920: Treatment-Free Remission in Chronic Myeloid Leukemia With Rare ABL1 Gene Fusions
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: CML-920 Treatment-Free Remission in Chronic Myeloid Leukemia With Rare ABL1 Gene Fusions
Clinical Lymphoma Myeloma & Leukemia·2025
Improving transparency and empowerment for cancer patients by accessing their full online personal medical records
Supportive Care in Cancer·2025
Treatment-free remission in chronic myeloid leukemia with rare ABL1 gene fusions: Real-life study from the French CML group Fi-LMC
Leukemia Research·2025· 1 cited
<i>18-Months Follow-up of the Trial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting</i>
Blood·2024· 1 cited
Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia
Leukemia Research·2024· 4 citedOpen Access
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission
Journal of Clinical Oncology·2024· 47 citedOpen Access
Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study
Leukemia Research·2024· 2 cited
Optimisation du bosutinib dans la leucémie myéloïde chronique : recommandations du Fi-LMC (France Intergroupe des leucémies myéloïdes chroniques)
Bulletin du Cancer·2023Open Access
Clinical, Cytogenetic and Molecular Characterization of a 96 MDS and AML Cohort with <i>TP53</i> Mutation
Blood·2023Open Access
<i>T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence</i>
Blood·2023· 2 cited
Poor Prognosis of SRSF2 Gene Mutations in Patients Treated with Venetoclax-Azacitidine (VEN-AZA) for Newly Diagnosed Acute Myeloid Leukemia. a Multicentric Real-Life Study of 117 Patients
Blood·2023· 1 citedOpen Access
PB1844: REAL: A RETROSPECTIVE STUDY OF THE CLINICO-BIOLOGICAL FEATURES OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES PATIENTS INCLUDED IN AN EARLY PHASE TRIAL AT A COMPREHENSIVE CANCER CENTER.
HemaSphere·2023Open Access
First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia
Leukemia Research·2023· 5 cited
Data from Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients
2023Open Access
Supplementary Data from Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients
2023Open Access
Supplementary Data from Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients
2023Open Access
Data from Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients
2023Open Access
Dasatinib plus <scp>Peg‐Interferon</scp> alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (<scp>DASA‐PegIFN</scp> study)
British Journal of Haematology·2022· 12 cited
page 1 of 8Next →

Frequent Co-authors

Delphine Réa(20), Gabriel Étienne(20), François‐Xavier Mahon(19), Norbert Vey(19), Laurence Legros(18), François Guilhot(17), Philippe Rousselot(17), Joëlle Guilhot(14), Franck E. Nicolini(14), Jérôme Rey(12), Françoise Huguet(11), Martine Gardembas(11), Thomas Prébet(10), Viviane Dubruille(9), Valérie Coiteux(9), Agnès Guerci(8), Bruno Varet(8), Martine Escoffre‐Barbe(8), Evelyne D’Incan(8), Marc Berger(7)